Hercules Capital upgraded by Keefe Bruyette with a new price target

Includes $30M at Close to Refinance Existing Debt Facility Savara Inc. (NASDAQ:SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with Hercules Capital, Inc. (NYSE:HTGC), for up to $200 million. Access to the additional capital strengthens Savara's balance sheet following the submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a treatment for autoimmune pulmonary alveolar proteinosis (aPAP). If Priority Review is granted by the FDA, MOLBREEVI could potentially be approved by the end of the year. The Comp

Convertible Unsecured Notes due 2028 Initially Assigned a BBB+ by Kroll Bond Rating Agency Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), today announced that it has closed a private offering of $287.5 million aggregate principal amount of its 4.750% Convertible Unsecured Notes due 2028 (the "Convertible Notes"), which amount includes the additional $37.5 million aggregate principal amount of Convertible Notes issued pursuant to the initial purchasers' exercise in full of its overallotment option. The Convertible Notes were sold only to qualified institutional buyers (as defined in the Securities Act of 1933, as amended (the "Securities Act")) pursuant to Rule 144A under

Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Morningstar DBRS ("DBRS") has upgraded Hercules' investment grade credit and corporate rating to BBB (high) from BBB with a trend revision from Positive to Stable, as well as its underlying analysis. "We are very pleased that DBRS has upgraded our investment grade credit and corporate rating to BBB (high) with a revised outlook to stable," stated Seth Meyer, chief financial officer of Hercules. "This

Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously

Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously

UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00

4 - Hercules Capital, Inc. (0001280784) (Issuer)

4 - Hercules Capital, Inc. (0001280784) (Issuer)

4 - Hercules Capital, Inc. (0001280784) (Issuer)

4 - Hercules Capital, Inc. (0001280784) (Issuer)

4 - Hercules Capital, Inc. (0001280784) (Issuer)

4 - Hercules Capital, Inc. (0001280784) (Issuer)

8-K - Hercules Capital, Inc. (0001280784) (Filer)

8-K - Hercules Capital, Inc. (0001280784) (Filer)

8-K - Hercules Capital, Inc. (0001280784) (Filer)

SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o

Record Full-Year 2024 Total Investment Income of $493.6 Million, an Increase of 7.1% Year-over-Year Record Full-Year 2024 Net Investment Income "NII" of $325.8 Million, an Increase of 7.2% Year-over-Year Record Full-Year 2024 Gross Fundings of $1.81 Billion, an Increase of 13.0% Year-over-Year Q4 2024 NII of $81.1 Million, or $0.49 per Share, provides 123% Coverage of the Base Cash Distribution Q4 2024 Total Gross Debt and Equity Commitments of $619.5 Million Q4 2024 Total Gross Fundings of $468.5 Million Conservative Balance Sheet Management with Net GAAP Leverage of 83.9% and Net Regulatory Leverage of 69.9% Inclusive of the Adviser Funds Managed by Hercules Adviser LLC, its

Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2024 financial results conference call for Thursday, February 13, 2025, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. To participate via telephone, please register here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can b

Record Q3 2024 Total Investment Income of $125.2 Million, an Increase of 7.3% Year-over-Year Q3 2024 Net Investment Income "NII" of $83.2 Million, or $0.51 per Share, an Increase of 8.3% Year-over-Year Q3 2024 NII Provides 128% Coverage of the Base Cash Distribution Q3 2024 Total Gross Debt and Equity Commitments of $430.7 Million Q3 2024 Total Gross Fundings of $272.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 92.5% and Net Regulatory Leverage of 83.0% Undistributed Earnings Spillover of $152.1 Million, or $0.94(1) per Ending Shares Outstanding Approximately $4.6 Billion of Assets Under Management, an Increase of 10.9% Year-over-Year(2) Hercules Capital

SC 13G - Hercules Capital, Inc. (0001280784) (Subject)

SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)

SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)